KRAS G12D mutations can upregulate NRF2 transcription through stimulation of the TPA response element (TRE) via MAPK signaling, providing a protective advantage to the cancer cells against chemotherapy-induced ROS [165,177,178]. Here, KRAS is linked to cancer.